首页> 美国卫生研究院文献>other >Melittin a major peptide component of bee venom and its conjugates in cancer therapy
【2h】

Melittin a major peptide component of bee venom and its conjugates in cancer therapy

机译:蜂毒的主要肽成分蜂毒肽及其结合物在癌症治疗中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
机译:蜂毒的主要肽成分蜂毒肽(MEL)是用于癌症治疗的有吸引力的候选药物。该药物在临床前细胞培养和动物模型系统中显示出多种抗癌作用。尽管有令人信服的针对多种癌症的功效数据,但由于包括非特异性细胞毒性,降解和溶血活性在内的几个问题,其对人类的适用性也面临挑战。包括利用基于纳米颗粒的MEL输送在内的几种优化方法已被用来规避这些问题。在这里,我们总结了当前对蜂毒和MEL的抗癌作用的不同认识。此外,我们还提供了有关蜂毒和/或MEL可能作用机制的可用信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号